Ticker: CRIS

Curis, Inc. (NASDAQ: CRIS) is a biotechnology company focused on developing emavusertib, an innovative small molecule inhibitor. The company reported its Q2 2025 financial results, providing insights into its performance and ongoing challenges. Key Financial Highlights for Q2 2025: Revenues: $2....

Curis, Inc. (NASDAQ: CRIS) has released its financial results for the quarter ended March 31, 2025, highlighting various critical aspects of its operations, challenges, and performance metrics. Positive Aspects: Revenue Growth: Revenue for the quarter increased 14% to $2.38 million compared to $...